- CEO
- Qi Mi
- Full Time Employees
- 990
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- South section of East Outer Ring Road, Heze SD China 274100
- IPO Date
- Jan 6, 2017
- Business
- Shandong Sito Bio-technology Co., Ltd. researches, develops, produces, and sells steroid biomedicine intermediates and raw materials for pharmaceutical companies using genetic engineering and microbial transformation technologies. The company offers core products including androstenedione (4-AD), 1,4-androstadiene-3,17-dione (ADD), 9-hydroxyandrostenedione (9OH-AD), 17α-hydroxyprogesterone, 17α-acetoxyprogesterone, progesterone intermediate (2DM), tetraene acetate (3TR), medroxyprogesterone (8DM), anecort acetate, tylvalosin tartrate, bisnoralcohol, norandrostenedione, estra-4,9-diene-3,17-dione, androsta-1,4-diene-3,17-dione, 16β and 16α methyl epoxide, and hexahydro-3α-methyl derivatives. Founded in 2002 and headquartered in Heze City, Shandong Province, China, the company operates primarily in the biopharmaceutical industry, serving global pharmaceutical manufacturers with production facilities covering 200,000 square meters and a dedicated R&D team. Shandong Sito maintains recognition as a national high-tech enterprise, Shandong Engineering Laboratory, and a leading enterprise in Shandong's top industrial clusters, with stable partnerships alongside gene sequencing firms and research institutes including Wuhan University and the Chinese Academy of Sciences. The company listed on the Shenzhen Stock Exchange in 2017 (ticker: 300583.SZ) and completed the acquisition of an 80% stake in Lisapharma S.p.A. in recent years to expand its operations.